EGFR and non-small cell lung carcinoma: In 2010, other studies(4) demonstrated the superiority of geftinib, an EGFR tyrosine kinase inhibitor as first line treatment of patients with advanced NSCLC, presenting with EGFR mutation at exons 19 and 21.